THE UTILITY OF SOX ANTIBODIES FOR CANCER PREDICTION IN PATIENTS WITH PARANEOPLASTIC NEUROLOGICAL DISORDERS

THE UTILITY OF SOX ANTIBODIES FOR CANCER PREDICTION IN PATIENTS WITH PARANEOPLASTIC NEUROLOGICAL DISORDERS

Detalhes bibliográficos
Principais autores:	Maddison, P, Titulaer, M, Verschuuren, J, Gozzard, P, Lang, B, Willcox, N, Vincent, A, Irani, SR, Chapman, C
Formato:	Conference item
Publicado em:	2012

Registros relacionados

The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders
por: Maddison, P, et al.
Publicado em: (2018)

Antibodies associated with paraneoplastic neurological disorders.
por: Vincent, A
Publicado em: (2005)

Algorithm to improve the diagnosis of paraneoplastic neurological syndromes associated with SOX1 antibodies
por: Cristina Arnaldos-Pérez, et al.
Publicado em: (2023-05-01)

Paraneoplastic neurological autoimmunity and survival in small-cell lung cancer.
por: Maddison, P, et al.
Publicado em: (2008)

Paraneoplastic neurological syndromes: a practical approach to diagnosis and management
por: Binks, S, et al.
Publicado em: (2021)

ANTI-HU PARANEOPLASTIC SENSORY NEURONOPATHY WITH UNDERLYING SQUAMOUS CELL CARCINOMA OF THE LUNG
por: Gozzard, P, et al.
Publicado em: (2010)

Recommended diagnostic criteria for paraneoplastic neurological syndromes.
por: Graus, F, et al.
Publicado em: (2004)

Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes.
por: Graus, F, et al.
Publicado em: (2005)

Review: Progress in the management of paraneoplastic neurological disorders
por: Hamid Sadeghian, et al.
Publicado em: (2010-01-01)

Paraneoplastic neurological syndromes. State of the art
por: Giometto, B, et al.
Publicado em: (2006)

Paraneoplastic neurological syndromes
por: Antoine Jean-Christophe, et al.
Publicado em: (2007-05-01)

Caveats and Pitfalls of SOX1 Autoantibody Testing With a Commercial Line Blot Assay in Paraneoplastic Neurological Investigations
por: Raquel Ruiz-García, et al.
Publicado em: (2019-04-01)

N-methyl-d-aspartate antibody encephalitis: Temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes
por: Irani, SR, et al.
Publicado em: (2010)

N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes.
por: Irani, SR, et al.
Publicado em: (2010)

Diagnosis of paraneoplastic neurological syndromes
por: Camilo E Fadul MD
Publicado em: (2007-07-01)

Diagnosis of paraneoplastic neurological syndromes
por: Camilo E Fadul MD
Publicado em: (2007-07-01)

PDE10A antibodies in autoimmune encephalitis: a possible marker of cancer immunotherapy?
por: Titulaer, MJ, et al.
Publicado em: (2019)

Antiganglioside antibodies and paraneoplastic neuromuscular junction disorder?
por: Noushin Jazebi, et al.
Publicado em: (2020-12-01)

EARLY AND CONTINUED TREATMENT OF N-METHYL D-ASPARTATE RECEPTOR-ANTIBODY ENCEPHALITIS OPTIMISES OUTCOME OF A PREDOMINANTLY NON-PARANEOPLASTIC DISEASE
por: Irani, SR, et al.
Publicado em: (2009)

An overview on CV2/CRMP5 antibody-associated paraneoplastic neurological syndromes
por: Sai Wang, et al.
Publicado em: (2023-01-01)

Anti-Ma2-antibody-associated encephalitis: An atypical paraneoplastic neurologic syndrome
por: Bogna Targonska, et al.
Publicado em: (2018-05-01)

Novel Humoral Prognostic Markers in Small-Cell Lung Carcinoma: A Prospective Study.
por: Paul Gozzard, et al.
Publicado em: (2015-01-01)

Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes
por: Daniel Chiu, et al.
Publicado em: (2023-07-01)

Neurological manifestation of cancer – paraneoplastic syndromes
por: Szklener Katarzyna, et al.
Publicado em: (2021-06-01)

Role of ion channel autoantibodies in NK-cell antibody-dependent anti-tumour immunity in patients with paraneoplastic Lambert-Eaton syndrome
por: Tschernatsch, M, et al.
Publicado em: (2009)

Simultaneous paraneoplastic cerebellar degeneration, Lambert-Eaton syndrome and neuropathy associated with AGNA/anti-SOX1 and VGCC antibodies
por: Jonas Feldheim, et al.
Publicado em: (2021-05-01)

Anti-Ma2 Antibody-Associated Paraneoplastic Neurological Syndromes: A Pilot Study
por: Yi Guo, et al.
Publicado em: (2021-11-01)

Antibody‐positive autoimmune encephalitis and paraneoplastic neurological syndrome: A Swedish case series
por: Sonja Kosek, et al.
Publicado em: (2024-05-01)

N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes
por: Irani, S, et al.
Publicado em: (2010)

Autoimmune and paraneoplastic seizures
por: Wagner, B, et al.
Publicado em: (2024)

Paraneoplastic neurologic syndrome: A practical approach
por: Sudheeran Kannoth
Publicado em: (2012-01-01)

Ovarian Teratoma-Related Paraneoplastic Neurological Syndromes
por: Jingfang Lin, et al.
Publicado em: (2022-05-01)

Paraneoplastic neurological syndromes: clinical presentations and management
por: Michelle F. Devine, et al.
Publicado em: (2021-01-01)

Predicting disability and mortality in CV2/CRMP5‐IgG associated paraneoplastic neurologic disorders
por: Sanem P. Uysal, et al.
Publicado em: (2024-03-01)

A case of paraneoplastic neurological syndrome expressing dual antineuronal antibodies: Anti-hu and recoverin
por: Ho-Sung Ryu, et al.
Publicado em: (2020-01-01)

P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer.
por: Graus, F, et al.
Publicado em: (2002)

Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia.
por: Becker, E, et al.
Publicado em: (2012)

Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia.
por: Becker, E, et al.
Publicado em: (2012)

Thymoma and paraneoplastic myasthenia gravis.
por: Marx, A, et al.
Publicado em: (2010)

Clinical characteristics and immunotherapy response in paraneoplastic neurologic syndrome patients with increased number of high-risk antibodies
por: Gong Wang, et al.
Publicado em: (2025-01-01)